Haematologica (Dec 2007)

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.

  • Pier Paolo Piccaluga,
  • Michele Malagola,
  • Michela Rondoni,
  • Mario Arpinati,
  • Stefania Paolini,
  • Anna Candoni,
  • Renato Fanin,
  • Emanuela Messa,
  • Maria Teresa Pirrotta,
  • Francesco Lauria,
  • Giuseppe Visani,
  • Daniele Alberti,
  • Francesca Rancati,
  • Vincenza Vinaccia,
  • Domenico Russo,
  • Giuseppe Saglio,
  • Michele Baccarani,
  • Giovanni Martinelli

DOI
https://doi.org/10.3324/haematol.11345
Journal volume & issue
Vol. 92, no. 12

Abstract

Read online

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5–44+). Non-hematologic toxicity was overall mild.